Literature DB >> 34734980

Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Lu Tian1, Bo Huang2, Lee-Jen Wei3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34734980      PMCID： PMC8776591          DOI： 10.1001/jamaoncol.2021.5605

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study.

Authors:  Bo Huang; Lu Tian; Enayet Talukder; Mace Rothenberg; Dae Hyun Kim; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

2.  Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.

Authors:  Bo Huang; Lu Tian; Zachary R McCaw; Xiaodong Luo; Enayet Talukder; Mace Rothenberg; Wanling Xie; Toni K Choueiri; Dae Hyun Kim; Lee-Jen Wei
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

3.  Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.

Authors:  Salma K Jabbour; Ki Hyeong Lee; Nikolaj Frost; Valeriy Breder; Dariusz M Kowalski; Theodore Pollock; Evgeny Levchenko; Noemi Reguart; Alex Martinez-Marti; Baerin Houghton; Jean-Baptiste Paoli; Sufia Safina; Keunchil Park; Takefumi Komiya; Amy Sanford; Vishal Boolell; Hong Liu; Ayman Samkari; Steven M Keller; Martin Reck
Journal:  JAMA Oncol       Date:  2021-06-04       Impact factor: 31.777
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.